Opinion|Videos|September 30, 2024
Overcoming Barriers to Prescribing First-Line Medications for CRM Conditions
Key Takeaways
- Enhancing physician awareness and understanding of SGLT2 inhibitors and GLP1-receptor agonists can increase prescription rates.
- Streamlining insurance approval processes and advocating for policy changes are crucial for improving medication coverage.
The expert panel analyzes strategies for overcoming barriers to prescribing first-line medications for cardiometabolic conditions.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Despite being approved for first-line treatment, medications such as SGLT2 inhibitors and GLP1-receptor agonists are not frequently prescribed to qualified patients. What has been effective in your practice to get these first line medications covered in the patient population who needs it the most?
This activity is supported by Boehringer Ingelheim Pharmaceuticals Inc. and Eli Lilly and Company who provided financial support for this program.
Advertisement
Related to this article
Insmed launches once-daily brensocatib in Japan, the country's only approved treatment for noncystic fibrosis bronchiectasis.
Cross-ancestry GWAS of more than 1.8 million people flags SERPINA1, SMAD3, and other bronchiectasis targets shared with COPD and chronic bronchitis.
The FDA approved bepirovirsen, the first antisense oligonucleotide for chronic hepatitis B, offering a new treatment with functional cure potential.
ALIS added to azithromycin and ethambutol raised culture conversion in new MAC lung disease, with rare resistance, in an ENCORE analysis at IDWeek 2026.
Insmed’s once-daily TPIP prodrug shows sustained lung vasodilation in PAH and PH-ILD, improving walk distance and other key measures.
Cosibelimab received an NCCN Category 2A preferred designation for locally advanced CSCC, supported by durable responses and low immune toxicity.
ASPEN links green sputum to neutrophils and exacerbations; brensocatib (DPP1) lowers purulence, while meta-analysis supports fewer flare-ups in bronchiectasis.
Experts at CHEST 2026 urge pulmonologists to keep lung cancer in mind for younger patients who never smoked, to order screening and biomarker testing themselves, and to advocate for patients' access to care.
Advertisement
Advertisement
Trending on AJMC
1
Bepirovirsen Approval Offers New Option for Chronic HBV Treatment
2
Inhaled Amikacin Raises Culture Conversion in New MAC Lung Disease
3
Uninsured Rate Rises to 11.2% as Coverage Erodes Before Medicaid Cuts
4
Bronchiectasis GWAS Highlights Candidate Targets Shared With COPD
5